US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer

Fourteen user fee goal dates are on the October calendar, including three novel agents, according to the Pink Sheet US FDA Performance Tracker.

pumpkin
• Source: Shutterstock

Pfizer Inc. can claim two of the three novel agents on the FDA’s user fee calendar for the month of October 2023, the Pink Sheet’s US FDA Performance Tracker shows.

Joining Pfizer’s oral ulcerative colitis therapy etrasimod and pentavalent meningococcal vaccine in the novel review queue is a candidate from...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers